STATE OF THE ART - LIVER DISEASE AND ITS INTERSECTION WITH DIABETES (DC-005)

Disclosure(s):

Manal Abdelmalak, MD, MPH: 89Bio: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Akero: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Boehringer-Ingelheim: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, March 18, 2022); Bristol-Myers Squibb: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, March 18, 2022); Celgene: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Chronic Liver DIsease Foundation: Speaker/Honoraria (Ongoing); Clinical Care Options: Speaker/Honoraria (Ongoing); Fishawack, Inc: Speaker/Honoraria (Ongoing); Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Gilead: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Hanmi: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Intercept: Consultant/Advisory Board (Terminated, June 23, 2023), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, June 23, 2023); Inventiva: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Madrigal: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medscape: Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Poxel: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); TARGET Pharma: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, March 18, 2022); Terra Firma, LLC: Speaker/Honoraria (Ongoing); Viking: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, March 18, 2022)

Zobair Younossi, MD: Abbott: Consultant/Advisory Board (Ongoing); Intercept: Consultant/Advisory Board (Ongoing); Madrigal: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Siemens: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

James W. Kim, MBBCh, PgDip, MScCH(HPTE): Abbott: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Academy for Continued Advancement in Healthcare Education: Speaker/Honoraria (Ongoing); AstraZeneca: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing); Boehringer-Ingelheim: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); CCRN: Speaker/Honoraria (Ongoing); CPD Network: Speaker/Honoraria (Ongoing); Eisai: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Embecta: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GSK: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); HIT Global: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Liv Agency: Speaker/Honoraria (Ongoing); MDBriefcase: Speaker/Honoraria (Ongoing); Miravo Pharm: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Moderna: Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); PPME: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Takeda: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Teva: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)